Cardiff Oncology (CRDF) Competitors $2.53 -0.09 (-3.44%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends CRDF vs. ADAP, ALGS, AGEN, DTIL, STRO, ALT, SANA, PROK, GLUE, and PRTCShould you be buying Cardiff Oncology stock or one of its competitors? The main competitors of Cardiff Oncology include Adaptimmune Therapeutics (ADAP), Aligos Therapeutics (ALGS), Agenus (AGEN), Precision BioSciences (DTIL), Sutro Biopharma (STRO), Altimmune (ALT), Sana Biotechnology (SANA), ProKidney (PROK), Monte Rosa Therapeutics (GLUE), and PureTech Health (PRTC). These companies are all part of the "medical" sector. Cardiff Oncology vs. Adaptimmune Therapeutics Aligos Therapeutics Agenus Precision BioSciences Sutro Biopharma Altimmune Sana Biotechnology ProKidney Monte Rosa Therapeutics PureTech Health Adaptimmune Therapeutics (NASDAQ:ADAP) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, community ranking, analyst recommendations, dividends, profitability, media sentiment, risk, earnings and valuation. Which has higher valuation and earnings, ADAP or CRDF? Cardiff Oncology has lower revenue, but higher earnings than Adaptimmune Therapeutics. Adaptimmune Therapeutics is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdaptimmune Therapeutics$60.28M2.82-$113.87M-$0.22-3.02Cardiff Oncology$490K264.00-$41.44M-$0.94-2.69 Do institutionals and insiders hold more shares of ADAP or CRDF? 31.4% of Adaptimmune Therapeutics shares are held by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are held by institutional investors. 12.4% of Adaptimmune Therapeutics shares are held by insiders. Comparatively, 7.8% of Cardiff Oncology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Do analysts prefer ADAP or CRDF? Adaptimmune Therapeutics currently has a consensus price target of $3.16, suggesting a potential upside of 375.78%. Cardiff Oncology has a consensus price target of $9.33, suggesting a potential upside of 268.91%. Given Adaptimmune Therapeutics' higher possible upside, equities research analysts plainly believe Adaptimmune Therapeutics is more favorable than Cardiff Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adaptimmune Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Cardiff Oncology 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk & volatility, ADAP or CRDF? Adaptimmune Therapeutics has a beta of 2.26, indicating that its stock price is 126% more volatile than the S&P 500. Comparatively, Cardiff Oncology has a beta of 1.93, indicating that its stock price is 93% more volatile than the S&P 500. Does the media refer more to ADAP or CRDF? In the previous week, Adaptimmune Therapeutics had 23 more articles in the media than Cardiff Oncology. MarketBeat recorded 25 mentions for Adaptimmune Therapeutics and 2 mentions for Cardiff Oncology. Adaptimmune Therapeutics' average media sentiment score of 0.43 beat Cardiff Oncology's score of 0.00 indicating that Adaptimmune Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adaptimmune Therapeutics 3 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 5 Negative mention(s) 0 Very Negative mention(s) Neutral Cardiff Oncology 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community prefer ADAP or CRDF? Adaptimmune Therapeutics received 276 more outperform votes than Cardiff Oncology when rated by MarketBeat users. However, 63.49% of users gave Cardiff Oncology an outperform vote while only 62.95% of users gave Adaptimmune Therapeutics an outperform vote. CompanyUnderperformOutperformAdaptimmune TherapeuticsOutperform Votes31662.95% Underperform Votes18637.05% Cardiff OncologyOutperform Votes4063.49% Underperform Votes2336.51% Is ADAP or CRDF more profitable? Adaptimmune Therapeutics has a net margin of -25.43% compared to Cardiff Oncology's net margin of -6,238.17%. Cardiff Oncology's return on equity of -73.97% beat Adaptimmune Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Adaptimmune Therapeutics-25.43% -74.15% -15.09% Cardiff Oncology -6,238.17%-73.97%-60.40% SummaryAdaptimmune Therapeutics beats Cardiff Oncology on 12 of the 17 factors compared between the two stocks. Ad WealthPressThis Bull Market Indicator called NVDA at $116Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…All you have to do is follow this link here Get Cardiff Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for CRDF and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRDF vs. The Competition Export to ExcelMetricCardiff OncologyBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$133.97M$2.93B$5.07B$8.89BDividend YieldN/A1.91%4.99%4.07%P/E Ratio-2.6915.0083.5712.93Price / Sales264.00280.711,220.3088.33Price / CashN/A168.0739.4636.25Price / Book2.614.696.936.25Net Income-$41.44M-$41.63M$119.12M$225.93M7 Day Performance-10.92%-4.73%-1.83%-1.32%1 Month Performance-8.66%-6.53%-3.64%0.60%1 Year Performance120.00%25.63%31.64%26.23% Cardiff Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRDFCardiff Oncology1.0829 of 5 stars$2.53-3.4%$9.33+268.9%+118.1%$133.97M$490,000.00-2.6920ADAPAdaptimmune Therapeutics2.1006 of 5 stars$0.66-1.5%$3.16+375.8%+54.9%$172.67M$60.28M0.00449Analyst RevisionALGSAligos Therapeutics4.1561 of 5 stars$18.20-1.6%$75.00+312.1%+5.5%$66.38M$15.53M-1.3790AGENAgenus3.8851 of 5 stars$2.67+3.9%$10.00+274.5%-82.0%$60.29M$156.31M0.00389Analyst RevisionDTILPrecision BioSciences4.0302 of 5 stars$7.18+0.3%$39.50+450.1%-46.6%$54.92M$48.73M119.69200Gap UpSTROSutro Biopharma4.5351 of 5 stars$2.67-1.1%$12.14+354.8%-3.6%$222.64M$153.73M0.00240Analyst ForecastAnalyst RevisionALTAltimmune1.9231 of 5 stars$8.05+7.8%$20.00+148.4%+206.1%$531.30M$430,000.000.0050Analyst RevisionSANASana Biotechnology2.22 of 5 stars$2.53+7.2%$13.50+433.6%-41.2%$526.91MN/A0.00328PROKProKidney2.5946 of 5 stars$1.65-8.3%$4.50+172.7%-6.3%$521.41MN/A0.003News CoverageGLUEMonte Rosa Therapeutics2.9578 of 5 stars$8.36+0.6%$16.00+91.4%+157.2%$510.54MN/A0.0090PRTCPureTech Health2.2392 of 5 stars$21.70+2.1%$45.00+107.4%+0.9%$508.96M$3.33M0.00100Analyst RevisionNews CoveragePositive News Related Companies and Tools Related Companies ADAP Competitors ALGS Competitors AGEN Competitors DTIL Competitors STRO Competitors ALT Competitors SANA Competitors PROK Competitors GLUE Competitors PRTC Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CRDF) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardiff Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cardiff Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CRDF Stock Alerts